Protein degradation in a LAMP-2-deficient B-lymphoblastoid cell line from a patient with Danon disease

Raul Sánchez-Lanzas1, Beatriz Alvarez-Castelao1, Teresa Bermejo1

  • 1Departamento de Bioquímica, Instituto de Investigaciones Biomédicas "Alberto Sols", UAM-CSIC y; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Facultad de Medicina UAM, 28029 Madrid, Spain.

Insights

Lamp-2 deficiency, linked to Danon disease, does not affect the degradation of key proteins in the chaperone-mediated autophagy (CMA) pathway. This study found no significant changes in protein levels or degradation rates in Lamp-2 deficient cells.

Area of Science:

  • Cellular Biology
  • Molecular Biology
  • Genetics

Background:

  • Danon disease is a genetic disorder caused by mutations in the LAMP-2 gene, leading to cardiomyopathy, myopathy, and intellectual disability.
  • The Lamp-2A protein is crucial for chaperone-mediated autophagy (CMA), a pathway responsible for selective protein degradation within lysosomes.

Purpose of the Study:

  • To investigate the role of Lamp-2 in protein degradation within the CMA pathway.
  • To determine if Lamp-2 deficiency impacts the steady-state levels and degradation of known CMA substrates.

Main Methods:

  • Established a Lamp-2 deficient lymphoblastoid cell line from a Danon patient.
  • Analyzed steady-state levels of CMA substrates (alpha-synuclein, IκBα, Rcan1, GAPDH) in control and Lamp-2 deficient cells.
  • Assessed protein half-life and degradation rates under various conditions, including proteasome inhibition and starvation-induced autophagy.

Main Results:

  • Lamp-2 deficient cells showed no significant difference in steady-state levels of alpha-synuclein, IκBα, Rcan1, or GAPDH compared to controls.
  • The degradation rates and half-lives of alpha-synuclein, IκBα, and Rcan1 were similar in both cell types.
  • Induction of CMA and macroautophagy led to comparable decreases in IκBα and Rcan1 levels in control and Lamp-2 deficient cells.

Conclusions:

  • Lamp-2 deficiency in human lymphoblastoid cells does not alter the steady-state levels or degradation of several identified CMA pathway substrates.
  • The findings suggest that other mechanisms may compensate for Lamp-2 deficiency in protein degradation within this cellular context.